CALEB ELMORE: Open Payments
NPI 1013322288 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$762 in 52 payments from 12 companies in 2025. Trend: 2023 $819 · 2024 $927 · 2025 $762
Food & beverage: $762
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $169 |
| Novartis Pharmaceuticals Corporation | 22 | $151 |
| United Therapeutics Corporation | 4 | $108 |
| Actelion Pharmaceuticals US, Inc. | 4 | $84 |
| PFIZER INC. | 3 | $57 |
| Merck Sharp & Dohme LLC | 3 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $28 |
| Medtronic, Inc. | 1 | $26 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
Products named: Wegovy, LEQVIO, Tyvaso, UPTRAVI, VYNDAQEL, VERQUVO, JARDIANCE, AMVUTTRA.
Industry payments across AL — which companies pay providers there.
